Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillatio…

Avirup Guha

R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…

Constantine Tam

ASCO® 2024 Insights: "CAPTIVATE Study - 5.5-Year Follow-Up Outcomes …

2024 ASCO® Annual Meeting Insights Hub

R. Jacobs

Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrilla…

Lydia Scarfò

EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax f…

Insights from 2024 EHA Annual Meeting

P. Ghia

Pirtobrutinib in CLL: Current and Potential Utility in the Treatment…

Nicole Lamanna

Guideline-Based Treatment Approaches in CLL

Farrukh Awan

Treatment Considerations for Initial Therapy of CLL

Indy Hematology Review

P. Hillmen